Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic … Read more
Gland Pharma Limited (GLAND) - Total Liabilities
Latest total liabilities as of September 2025: ₹22.37 Billion INR
Based on the latest financial reports, Gland Pharma Limited (GLAND) has total liabilities worth ₹22.37 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gland Pharma Limited - Total Liabilities Trend (2017–2025)
This chart illustrates how Gland Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gland Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Gland Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Region Group
AU:RGN
|
Australia | AU$1.81 Billion |
|
O-I Glass Inc
NYSE:OI
|
USA | $6.93 Billion |
|
X Trade Brokers Dom Maklerski SA
WAR:XTB
|
Poland | zł6.51 Billion |
|
Longboard Pharmaceuticals Inc
NASDAQ:LBPH
|
USA | $21.82 Million |
|
Sharp Corporation
PINK:SHCAF
|
USA | $1.17 Trillion |
|
Universal Technical Institute Inc
NYSE:UTI
|
USA | $498.03 Million |
|
Insignia Financial Ltd
AU:IFL
|
Australia | AU$1.70 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Gland Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gland Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gland Pharma Limited (2017–2025)
The table below shows the annual total liabilities of Gland Pharma Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹20.74 Billion | +7.06% |
| 2024-03-31 | ₹19.37 Billion | +136.61% |
| 2023-03-31 | ₹8.19 Billion | +21.13% |
| 2022-03-31 | ₹6.76 Billion | +14.03% |
| 2021-03-31 | ₹5.93 Billion | +34.80% |
| 2020-03-31 | ₹4.40 Billion | -33.52% |
| 2019-03-31 | ₹6.62 Billion | +27.44% |
| 2018-03-31 | ₹5.19 Billion | +35.21% |
| 2017-03-31 | ₹3.84 Billion | -- |